Ann: CardieX Corporate Update & Overview of inHealth Transaction, page-3

“Our vision is to build the largest global Telehealth company…” - Cardiex CEO Craig R Cooper.

While I commend Cardiex’s vision, I’d like to see Cooper set a timeline in the next Investor Update. And run a list of the world’s current top telehealth companies that Cardiex intends to emulate.

The latest 41pp Update suggests the group is on the move.

Staff numbers have climbed 50pc to 24 not including six engineers the group is sharing with its Silicon Valley-based Blumio wearables affiliate.

Forecast turnover for 2019 is $4.22m. That’s up a modest 8% on 2018 turnover of $4.01m but still short of the $4.33m scored in 2017.

It’s in 2020 that turnover is set to treble to $12m as the group gains 51% control of the LA-based inHealth Medical Services telehealth/coaching operation.

Craig Cooper seems likely to join the inHealth board and help expand business with $ANTM/Anthem, #2 ranking US health insurer and American Well, #1 ranking US telemedicine provider.

These are big names. But they’re not the only ones. With its FDA-approved XCEL SphygmoCor central arterial blood pressure device Cardiex has relationships with Cleveland Clinic, Mayo Clinic, Emory U, AstraZeneca, GSK, Novartis and Suntech Medical.

While propelling business with these groups, Cooper has other challenges - like energizing lackluster performance in China.

And addressing housekeeping issues - such as overcoming delays in the launch of the cardiex.com website.

Meantime, I think Rikardo is right - it will take time for “green shoots” (profits) to grow.

But with a market cap of $18m, CDX has a lot of upside. I’m expecting the SP to treble within 12 months.